29 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalised medicine (MultipleMS)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
The complex interactions between genetic and non-genetic factors produce heterogeneities in patients as reflected in the diversity of pathophysiology, clinical manifestations, response to therapies, disease development and progression. Yet, the full potential of personalized medicine entails biomarker-guided delivery of efficient therapies in stratified patient populations.MultipleMS will therefor ...
Voir le projet
25
Participants partenaires
TERMINÉ
Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging with ‘Minimally-Invasive Segmental Artery Coil-Embolization’: A Randomized Controlled Multicentre Trial (PAPA-ARTIS)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
Chronic aortic aneurysms are permanent and localized dilations of the aorta that remain asymptomatic for long periods of time but continue to increase in diameter before they eventually rupture. Left untreated, the patients’ prognosis is dismal, since the internal bleeding of the rupture brings about sudden death. Although successful treatment cures the disease, the risky procedures can result in ...
Voir le projet
26
Participants partenaires
TERMINÉ
Molecule-to-man pain network (PAIN-Net)
Date du début: 1 févr. 2017, Date de fin: 31 janv. 2021,
Neuropathic pain affects 5% of the general population and 40% of patients with neurological diseases, and has a key role in the pathophysiology of cancer pain that affects up to 50% of patients in the early disease stage and 30% of survivors, causing an enormous social burden. Treatments are inadequate with less than 50% of patients achieving 50% of pain relief at best, while up to 30% of cancer p ...
Voir le projet
13
Participants partenaires
TERMINÉ
EURopean Endeavour for Chimeric Antigen Receptor Therapies (EURE-CART)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2020,
Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases. Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing ...
Voir le projet
11
Participants partenaires
TERMINÉ
Smart optical and ultrasound diagnostics of breast cancer (SOLUS)
Date du début: 1 déc. 2016, Date de fin: 30 nov. 2020,
SOLUS is a trans-disciplinary 48-month project bringing together 9 partners: industries (4), academic and clinical institutions from 5 countries (engineers, physicists and radiologists) representing cutting-edge expertise in their fields, to develop an innovative non-invasive, point-of-care, low-cost, easy-to-operate, multi-modal imaging system (diffuse optics and ultrasounds/shear wave elastograp ...
Voir le projet
10
Participants partenaires
TERMINÉ
European AIDS Vaccine Initiative 2020 (EAVI2020)
Date du début: 1 nov. 2015, Date de fin: 31 oct. 2020,
HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradicati ...
Voir le projet
27
Participants partenaires
TERMINÉ
Beta Cell Generation by Stem Cell-Derived Implants in Diabetes (BetaCellTherapy)
Date du début: 1 déc. 2015, Date de fin: 31 août 2020,
Despite improved treatment, diabetes remains a chronic disease with major health risks and heavy burden on patients and society. Serious forms are caused by depletion in pancreatic beta cells and associated loss in insulin’s homeostatic control throughout life. Their cure requires restoration of a metabolically adequate beta cell mass. Implants of beta cell grafts prepared from human pancreases ha ...
Voir le projet
8
Participants partenaires
TERMINÉ
DITAS: Data-intensive applications Improvement by moving daTA and computation in mixed cloud/fog environmentS (DITAS)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2019,
There is an increasing need to develop data intensive applications able to manage more and more amounts of data coming from distributed and heterogeneous sources effectively, quickly, correctly, and securely. However, the current adoption of Cloud Computing paradigm is not fully appropriate to store and analyse such data: latency, security, and compliance are still significant barriers. At the sa ...
Voir le projet
9
Participants partenaires
TERMINÉ
Chimeric Antigen Receptors (CARs) for Advanced Therapies (CARAT)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T-cell receptors. In this respect, CARs are increasingly used for cellular therapy to redirect T-cells specifically towards killing of cancer cells. Recent success stories of cancer therapy with CAR modified T-c ...
Voir le projet
9
Participants partenaires
TERMINÉ
DevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID) (SCIDNET)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Severe combined immunodeficiency (SCID) is a devastating rare disorder of immune system development. Affected infants are born without functional immune systems and die within the first year of life unless effective treatment is given. Treatment options are limited to allogeneic haematopoietic stem cell transplantation and autologous stem cell gene therapy. Over the last 15 years, gene therapy for ...
Voir le projet
13
Participants partenaires
TERMINÉ
Neurovascular Interactions and Pathfinding in the Spinal Motor System (NEVAI)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2019,
"Neurons and blood vessels rely on common guidance signals to wire into elaborate neural and vascular networks that are closely juxtaposed and interdependent: vascular supply of oxygen and nutrients is essential to sustain the high metabolic rate of the nervous system, and conversely neural control of vascular tone is crucial for circulatory homeostasis. However, it remains unclear how the nervous ...
Voir le projet
2
Participants partenaires
TERMINÉ
IMMUNOMETABOLISM IN HUMAN OBESITY (Fit-The-Fat)
Date du début: 1 sept. 2017, Date de fin: 31 août 2019,
The incidence of obesity and type 2 diabetes (T2D) are inexorably increasing and elevated healthcare costs related to the higher disease-associated morbidity are affecting European and extra-European countries. Obesity is associated with resistance to the action of insulin (called insulin-resistance) in adipocytes, which is thought to be induced by a low-grade inflammation present in the adipose t ...
Voir le projet
2
Participants partenaires
TERMINÉ
HSC-based therapies for LSDs: understanding the modalities of cell replacement in the LSD brain for improving therapeutic efficacy (HSCSFORLSDBRAIN)
Date du début: 1 juin 2014, Date de fin: 31 mai 2019,
The recent hypothesis that postnatal microglia are maintained independently of circulating monocytes by local precursors that colonize the brain before birth has relevant implications for the treatment of various neurological diseases, including lysosomal storage disorders (LSDs). LSDs are fatal diseases of childhood occurring in 1:5000-7000 live births; in >50% of the cases, LSD patients experien ...
Voir le projet
2
Participants partenaires
TERMINÉ
New experimental therapeutic approaches for Parkinson’s disease by direct DA neuronal reprogramming (REPROPARK)
Date du début: 1 juin 2014, Date de fin: 31 mai 2019,
Neurodegenerative diseases cause a significant burden on the elderly population in Europe. Parkinson’s disease (PD) affects 1.2 million people in Europe and with the increasing life expectancy this number will rise, putting more pressure on health care. Treatment of PD is only symptomatic, and therefore, there is an urgent need for more efficient therapies. Degeneration of mesencephalic DA neurons ...
Voir le projet
2
Participants partenaires
TERMINÉ
Adoptive engineered T cell Trials to Achieve Cancer Killing (ATTACK)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2017,
The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer. Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results. However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials ...
Voir le projet
16
Participants partenaires
TERMINÉ
Avrupada Sağlık Politikalarının Öğrenilmesi ve Ülkemize Taşınması Projesi
Date du début: 1 juin 2015, Date de fin: 31 mai 2016,
...e control of 2 accompanying teachers from Sis Vocational and Technical High School will receive training on Emergency Medical Technician and Information and Communication Technologies in Italy at Ospedale San Raffaele hospital.
2nd Visit: 10 students under the control of 2 accompanying teachers from Sis Vocational and Technical High School will receive training on Clerkship for Medical Emergen ...
Voir le projet
5
Participants partenaires
TERMINÉ
Yaşlı ve Zihinsel Engelli Hasta Bakımlarında Avrupa Uygulamalarının Transferi
Date du début: 1 juin 2015, Date de fin: 31 mai 2016,
In this century, health care systems and the education of health sector have undergone so many compulsory changes due to technological innovations, demographic changes and huge collection of knowledge. The vision of nursing embodies new roles in the aspects of both protective and therapeutic means. Our project includes health services such as care of old people or the handicapped which have been r ...
Voir le projet
3
Participants partenaires
TERMINÉ
Imaging liver immunopathology by intravital microscopy (IVM): a new approach to study the pathogenesis of hepatitis B virus (HBV) infection (Liver IVM and HBV)
Date du début: 1 sept. 2010, Date de fin: 31 mars 2016,
Overall objective and Specific Aims. The overall objective of this proposal is to elucidate the pathogenesis ofHBV infection with the ultimate hope that this knowledge will lead to the development of new therapeuticstrategies to terminate persistent infection and its attendant costs and complications. Our approach is to dissectpoorly understood cellular and molecular pathways responsible for both ...
Voir le projet
2
Participants partenaires
TERMINÉ
Towards Safe and Effective Hematopoietic Stem Cell Gene Therapy: Targeting Integration to Genomic Safe Harbors and Exploiting Endogenous microRNA to Regulate Transgene Expression (TARGETINGGENETHERAPY)
Date du début: 1 mai 2010, Date de fin: 31 janv. 2016,
Hematopoietic stem cell gene therapy has a tremendous potential to treat human disease. Yet, in conjunction with the first successful results in the clinic, severe adverse events linked to the gene transfer protocol were reported. Recently, we provided proof-of-principle of two new powerful strategies to improve the efficacy and safety of gene transfer: 1) regulating transgene expression by exploi ...
Voir le projet
3
Participants partenaires
TERMINÉ
Effect of PTPN22 on Treg to Teff equilibrium in human and murine autoimmune diabetes (PTPN22 in T1D)
Date du début: 1 avr. 2011, Date de fin: 31 mars 2015,
"Type 1 diabetes (T1D) is a chronic inflammatory disease, where predisposing genetic factors along with environmental influences result in loss of immunological tolerance and destruction of insulin-producing beta cells. Genetic studies have identified three main T1D susceptibility loci, the human leukocyte antigens (HLA), insulin and most recently PTPN22, which encodes for Lyp/Pep, a lymphoid tyro ...
Voir le projet
2
Participants partenaires
TERMINÉ
Aberrant gene expression and muscular dystrophy: role of non-coding RNAs and alternative splicing in the pathogenesis and potential therapies (NCRNAS-SPLICING-FSHD)
Date du début: 1 sept. 2008, Date de fin: 31 août 2014,
Our goal is to characterize the molecular pathogenesis of facioscapulohumeral muscular dystrophy (FSHD) in order to develop possible therapeutic approaches. FSHD is the third most important myopathy. Currently, no therapeutic treatment is available for FSHD. Unlike the majority of genetic diseases, FSHD is not caused by mutation in a protein-coding gene. Instead, FSHD is the result of a complex ep ...
Voir le projet
2
Participants partenaires
TERMINÉ
Immunomodulatory Effects of Exercise in Type 1 Diabetes (IMMEEDIA)
Date du début: 1 juil. 2010, Date de fin: 30 juin 2014,
"Diabetes is a major metabolic disease with huge costs for healthcare system throughout the EU and worldwide. Type 1 Diabetes (T1DM) is a chronic condition in which pancreas produces little or no insulin, believed to result from a disorder of immunoregulation. For decades it has been known that regular aerobic exercise improves insulin sensitivity in diabetic patients, reducing insulin requirement ...
Voir le projet
5
Participants partenaires
TERMINÉ
Role of secretases in myelination (Secretases & Myelin)
Date du début: 1 mai 2010, Date de fin: 30 avr. 2014,
The development of glial cells, oligodendrocytes (OL) in CNS and Schwann cells (SC) in PNS, critically depends on axonal contact. Gliogenesis and the phenotype of myelinating glia are regulated by axons. Glial cells promote neuronal survival, regulate the organization of myelinated axons and promote axonal differentiation and myelin sheath production.We recently showed that type III NRG1, a member ...
Voir le projet
2
Participants partenaires
TERMINÉ
Linking research organisations in the fields of Tissue Engineering and Regenerative Medicine through European cooperation between regional research clusters (TERM)
Date du début: 1 oct. 2010, Date de fin: 30 sept. 2013,
"The development of innovative 'Advanced Therapies' offers new approaches to tackle major diseases such as cancer, diabetes, Alzheimer or Parkinson. The progress made in the fields of 'Tissue Engineering' and 'Regenerative Medicine' (TERM) promises to deliver long awaited new solutions. They are recognized as potential sources for medical progress and significant economic growth where Europe shoul ...
Voir le projet
16
Participants partenaires
TERMINÉ
Novel therapeutic antibodies for multiple myeloma (MMSC)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2013,
"Multiple Myeloma (MM) is an incurable plasma cell neoplasm with a median survival of 3 years. A critical step towards the development of more effective therapies is the identification of dominantly acting oncogenes. We have implemented an integrated oncogenomic approach that utilizes high-resolution gene-specific array-CGH and comprehensive expression profiling to identify the spectrum of geneti ...
Voir le projet
2
Participants partenaires
TERMINÉ
Advanced Teaching and TRaining for Adoptive Cell Therapy (ATTRACT)
Date du début: 1 oct. 2009, Date de fin: 30 sept. 2013,
Considerable resources are devoted to fighting cancer throughout Europe, yet these efforts are not producing the results that health practitioners and citizens might expect. This is partly due to the fragmentation and duplication of research efforts within Member states and the lack of co-ordination at European level. However it can also be attributed to the need to retain and most importantly dev ...
Voir le projet
16
Participants partenaires
TERMINÉ
Experiential Living Lab for the Internet Of Things (ELLIOT)
Date du début: 1 sept. 2010, Date de fin: 30 juin 2013,
The ELLIOT project aims to develop an Internet Of Things (IOT) experiential platform where users/citizens are directly involved in co-creating, exploring and experimenting new ideas, concepts and technological artefacts related to IOT applications and services. ELLIOT will allow studying the potential impact of IOT and the Future Internet in the context of the Open User Centred Innovation paradigm ...
Voir le projet
13
Participants partenaires
TERMINÉ
Role of angiogenesis in leukemia (leukemia and VEGF)
Date du début: 1 janv. 2009, Date de fin: 31 déc. 2012,
Our interest is to understand the role of VEGF expression and angiogenesis in leukemogenesis. Recently, emerging data is suggesting that in addition to promoting the growth and metastatic spread of solid tumors, angiogenesis may play an important role also in the pathophysiology of hematological malignancies. Clinical studies indicate that leukemia patients express high levels of pro-angiogenic fa ...
Voir le projet
2
Participants partenaires
TERMINÉ
Next Generation HIV-1 Immunogens inducing broadly reactive Neutralising antibodies (NGIN)
Date du début: 1 févr. 2008, Date de fin: 31 juil. 2012,
"The elicitation of broadly neutralising antibodies (Nab) remains the primary and most challenging goal in HIV-1 vaccine development. Although a few anti-HIV-1 monoclonal antibodies with broadly neutralising capability have been isolated from infected individuals, none of the immunization strategies thus far explored has proven effective in inducing similar antibodies. Objective of this applicatio ...
Voir le projet